本报道最初发表于Endpoints News。请点击这里查看原文
Two years ago, CRISPR gene editing pioneer Feng Zhang and former Illumina chief technology officer Alex Aravanis launched a startup to develop medicines that would change how genes are turned on and off without altering DNA itself.
两年前,CRISPR基因编辑先驱张锋(Feng Zhang)与前因美纳(Illumina)首席技术官亚历克斯·阿拉瓦尼斯(Alex Aravanis)创办了一家初创公司,致力于开发无需改变DNA本身即可调控基因开关的药物。
您已阅读6%(374字),剩余94%(5552字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。